Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) is now available.
JPMorgan Chase & Co. and its affiliates have ceased to be substantial holders in Clarity Pharmaceuticals Ltd., as indicated in their recent notice. This change in holdings could impact Clarity’s market dynamics and shareholder structure, potentially affecting investor confidence and the company’s strategic direction.
The most recent analyst rating on (AU:CU6) stock is a Hold with a A$5.00 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of radiopharmaceuticals for the treatment of serious diseases. The company is committed to advancing its pipeline of targeted therapies to address unmet medical needs.
Average Trading Volume: 2,703,193
Technical Sentiment Signal: Hold
Current Market Cap: A$1.34B
See more data about CU6 stock on TipRanks’ Stock Analysis page.